The development of effective targeted therapies for triple negative breast cancer (TNBC) remains a challenge. This targeted drug delivery system used a near-infrared fluorescence dye cyanine 5.5 (Cy5.5) and an ICAM-1 antibody on thioether-bridged periodic mesoporous organosilica nanoparticles (PMOs). The ICAM-1 antibody and cyanine 5.5-engineered PMOs (PMO-Cy5.5-ICAM) offer excellent in vivo and in vitro biocompatibility. The PMO-Cy5.5-ICAM shows a loading capacity up to 400 mg/g of doxorubicin (DOX). The drug release profile of the DOX-loaded targeted delivery system ([email protected]) is pH-sensitive. Confocal microscopy showed that the PMO-Cy5.5-ICAM efficiently targets and enters TNBC cells. In in vivo experiments, the [email protected] accumulates more in TNBCs than in the control groups and exhibits better therapeutic effects on TNBC; thus, it is a promising treatment strategy for TNBC.

对于三阴性乳腺癌（TNBC）的有效靶向疗法的发展仍然是一个挑战。该靶向药物递送系统在硫醚桥连的周期性介孔有机二氧化硅纳米粒子（PMO）上使用了近红外荧光染料花青5.5（Cy5.5）和ICAM-1抗体。ICAM-1抗体和花青5.5修饰的PMO（PMO-Cy5.5-ICAM）具有出色的体内和体外生物相容性。PMO-Cy5.5-ICAM显示出高达400 mg / g的阿霉素（DOX）负载量。装有DOX的靶向递送系统（[受电子邮件保护]）的药物释放曲线对pH敏感。共聚焦显微镜显示，PMO-Cy5.5-ICAM有效靶向并进入TNBC细胞。在体内实验中，受保护的电子邮件在TNBC中的蓄积量大于对照组，并且对TNBC表现出更好的治疗效果；因此，它是TNBC的有前途的治疗策略。